AlphAIAlphAI — Financial news for AI agents
rttnews.comAUG 32 min read$HELP

Helus Pharma Appoints Michael Halstead CEO, Effective Immediately

According to Cybin D/B/A Helus Pharma (HELP), it appointed Michael Halstead as Chief Executive Officer effective immediately. The company said Halstead has 25 years of industry experience, most recently as President of Intra-Cellular Therapies (ITCI). In Nasdaq pre-market, HELP shares were down 0.90% to $7.75 after Friday’s 3.93% decline.

Original reporting
rttnews.com
Published Aug 3, 2026, 4:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 3, 2026, 4:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$HELP
Neutral
medium confidence
Mentioned
$HELP
Relevance
4/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$HELPNeutralLow
01

Why it matters

A new CEO can influence near-term sentiment, but the text lacks any new guidance, trial readouts, or deal activity that would drive a decisive repricing.

02

Market read

Traders may monitor for follow-on announcements from Helus Pharma, but this specific report contains no new financial or clinical catalysts.

03

What to watch

Investors will likely wait for Halstead’s first strategic communications, board priorities, and any follow-on changes to R&D or financing plans.

Relevance 4/10Novelty 4/10Timing: effective immediately, pre-market trading context mentioned

Background

The article frames the CEO appointment and Halstead’s prior roles, including President of Intra-Cellular Therapies.

Company-level read

Ticker impact

$HELPNeutralMedium confidence
Context

Helus Pharma appointed Michael Halstead as CEO effective immediately, a direct leadership change for the company.

Expected impact

Likely limited near-term impact unless accompanied by strategy updates or new clinical/financing milestones.

Evidence & confidence

The only new company-specific fact is the CEO change; there are no new trial results, contracts, or capital actions disclosed.

Market effects

Sector

Leadership changes are common in biotech and can affect perceived execution risk, but no sector-wide signal is provided.

Regional

None indicated beyond Nasdaq pre-market mention.

Global

None indicated.

Counterpoint

What could challenge this read

The market may be overreacting to the CEO headline; without new strategy or pipeline updates, the move may not change fundamentals.

Key entities

  • company
    Helus Pharma

    Subject of the article, announcing a CEO appointment effective immediately.

  • person
    Michael Halstead

    Incoming CEO with 25 years of industry experience, most recently President of Intra-Cellular Therapies.

  • company
    Intra-Cellular Therapies, Inc.

    Most recent employer of the incoming CEO, cited for background only.

Read at source← All news

Related articles

AUG 14
$HELPMed

Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights

Helus Pharma (Nasdaq: HELP) reported fiscal Q1 2027 results for the quarter ended June 30, 2026. Cash was $166.4M. Net loss was $47.8M vs $24.6M a year earlier. The company said Phase 3 APPROACH enrollment for HLP003 in MDD is complete with topline data expected in Q4 2026, and a DDI study showed no meaningful PK interaction. It also completed a $50M underwritten offering in June 2026.

finanznachrichten.de6 min
JUL 21
$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min
JUL 17
$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min
JUN 25
$HELPMedAI 8/10

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

montrealgazette.com2 min
SEP 9
$USDEMed

StablecoinX Names New CEO to Oversee ENA Treasury

StablecoinX (USDE) named Christopher Jensen, a former Franklin Templeton digital asset executive, as its new CEO. Jensen succeeds Ted Chen, who will remain chairman. StablecoinX is the largest corporate holder of Ethena’s ENA token, with about 3.03 billion tokens, or 20% of the total supply. ENA, Ethena’s governance token, has gained over 80% in the past month to trade around $0.16, according to CoinGecko.

cointelegraph.com1 min